From revolutionary science to the impact of Obamacare, every week The Motley Fool's health-care team sits down to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about the disruptive potential of a new iPhone app, as well as an FDA inquiry that could have negative implications for some of the pharmaceutical industry's biggest players. In addition, our analysts dive into some of the stocks making big moves over the past week and discuss companies on their radar for the near future.

In the following segment, health-care analyst David Williamson discusses a stock to watch in the coming weeks: Sarepta. The biotech has a number of critical catalysts that could propel the stock to new highs or send it plunging lower. Find out why investors need to have Sarepta on their radar going into an important FDA decision in April.

The relevant video segment can be found between 12:43  and 14:21.